Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN Trial): A Randomized Placebo-Controlled Clinical Trial

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2024 Feb 28

PMID 38416033

Authors

Line A Mortensen

Bente Jespersen

Anne Sophie L Helligsoe

Birgitte Tougaard

Donata Cibulskyte-Ninkovic

Martin Egfjord

Lene Boesby

Niels Marcussen

Kirsten Madsen

Boye L Jensen

Inge Petersen

Claus Bistrup

Helle C Thiesson

Affiliations

Soon will be listed here.

Citing Articles

Mineralocorticoid receptor antagonism for non-diabetic kidney disease.

Jaisser F, Barrera-Chimal J Nephrol Dial Transplant. 2025; 40(Supplement_1):i29-i36.

PMID: 39907538 PMC: 11795674. DOI: 10.1093/ndt/gfae241.

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review.

Miyasako K, Maeoka Y, Masaki T Biomedicines. 2025; 13(1).

PMID: 39857638 PMC: 11760469. DOI: 10.3390/biomedicines13010053.

Mineralocorticoid receptor blockage in kidney transplantation: too much of a good thing or not?.

Afsar B, Afsar R, Caliskan Y, Lentine K Int Urol Nephrol. 2024; 57(3):839-854.

PMID: 39470940 DOI: 10.1007/s11255-024-04256-6.

Antihypertensive treatment for kidney transplant recipients.

Natale P, Mooi P, Palmer S, Cross N, Cooper T, Webster A Cochrane Database Syst Rev. 2024; 7():CD003598.

PMID: 39082471 PMC: 11290053. DOI: 10.1002/14651858.CD003598.pub3.

Benefit of Renin Angiotensin Aldosterone Blockade in Kidney Transplant Recipients: Is the Verdict in or Still to Be Answered?.

Sawinski D, Mottl A Clin J Am Soc Nephrol. 2024; 19(6):691-693.

PMID: 38758607 PMC: 11168816. DOI: 10.2215/CJN.0000000000000479.

References

Vidal-Petiot E, Courbebaisse M, Livrozet M, Correge G, Rusu T, Montravers F . Comparison of Cr-EDTA and Tc-DTPA for glomerular filtration rate measurement. J Nephrol. 2021; 34(3):729-737. DOI: 10.1007/s40620-020-00932-9. View

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309-21. DOI: 10.1056/NEJMoa030207. View

Brown N . Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013; 9(8):459-69. PMC: 3922409. DOI: 10.1038/nrneph.2013.110. View

J T, L B, T H, J R, M W, M H . Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018; 10:80-85. PMC: 5898524. DOI: 10.1016/j.conctc.2018.03.008. View

Vardeny O, Wu D, Desai A, Rossignol P, Zannad F, Pitt B . Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012; 60(20):2082-9. DOI: 10.1016/j.jacc.2012.07.048. View

Bakris G, Agarwal R, Anker S, Pitt B, Ruilope L, Rossing P . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219-2229. DOI: 10.1056/NEJMoa2025845. View

Riella L, Djamali A, Pascual J . Chronic allograft injury: Mechanisms and potential treatment targets. Transplant Rev (Orlando). 2016; 31(1):1-9. DOI: 10.1016/j.trre.2016.10.005. View

Silva F, Miorin L, Sens Y . The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A. Ren Fail. 2008; 30(4):439-42. DOI: 10.1080/08860220801947397. View

Thomsen Nielsen F, Jensen B, Marcussen N, Skott O, Bie P . Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. Nephrol Dial Transplant. 2008; 23(9):2777-83. DOI: 10.1093/ndt/gfn204. View

10.

Thomsen Nielsen F, Jensen B, Hansen P, Marcussen N, Bie P . The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrol. 2013; 14:42. PMC: 3602207. DOI: 10.1186/1471-2369-14-42. View

11.

Kasiske B, Gaston R, Gourishankar S, Halloran P, Matas A, Jeffery J . Long-term deterioration of kidney allograft function. Am J Transplant. 2005; 5(6):1405-14. DOI: 10.1111/j.1600-6143.2005.00853.x. View

12.

Medeiros M, Velasquez-Jones L, Hernandez A, Ramon-Garcia G, Valverde S, Fuentes Y . Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy. Clin J Am Soc Nephrol. 2017; 12(8):1291-1300. PMC: 5544507. DOI: 10.2215/CJN.05300516. View

13.

McAuley F, Whiting P, Thomson A, Simpson J . The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity. Biochem Pharmacol. 1987; 36(5):699-703. DOI: 10.1016/0006-2952(87)90721-0. View

14.

Currie G, Taylor A, Fujita T, Ohtsu H, Lindhardt M, Rossing P . Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016; 17(1):127. PMC: 5015203. DOI: 10.1186/s12882-016-0337-0. View

15.

Sun Q, Li M, Rui H, Chen Y . Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity. J Renin Angiotensin Aldosterone Syst. 2014; 16(2):301-10. DOI: 10.1177/1470320314561248. View

16.

Pitt B, Zannad F, Remme W, Cody R, CASTAIGNE A, Perez A . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. DOI: 10.1056/NEJM199909023411001. View

17.

Morales-Buenrostro L, Ortega-Trejo J, Perez-Villalva R, Marino L, Gonzalez-Bobadilla Y, Juarez H . Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial. Am J Physiol Renal Physiol. 2019; 317(3):F519-F528. DOI: 10.1152/ajprenal.00606.2018. View

18.

Macunluoglu B, Arikan H, Atakan A, Tuglular S, Ulfer G, Cakalagaoglu F . Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc. 2008; 40(1):273-8. DOI: 10.1016/j.transproceed.2007.11.025. View

19.

Naesens M, Kuypers D, Sarwal M . Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4(2):481-508. DOI: 10.2215/CJN.04800908. View

20.

Perez-Rojas J, Derive S, Blanco J, Cruz C, Martinez de la Maza L, Gamba G . Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2005; 289(5):F1020-30. DOI: 10.1152/ajprenal.00166.2005. View